Novel Compounds as PKC-Theta Inhibitors for Treating Autoimmune or Inflammatory Diseases

Provided herein are novel compounds as PKC-theta inhibitors, pharmaceutical compositions, use of such compounds in treating autoimmune or inflammatory diseases, and processes for preparing such compounds.

Authors

Publication Details

Journal
ACS Medicinal Chemistry Letters
Published
2026-01-07
DOI
https://doi.org/10.1021/acsmedchemlett.5c00765
Primary Topic
Protein Kinase Regulation and GTPase Signaling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel Compounds as PKC-Theta Inhibitors for Treating Autoimmune or Inflammatory Diseases

R. W. Sabnis
ACS Medicinal Chemistry Letters
Protein Kinase Regulation and GTPase Signaling
article

Novel Compounds as PKC-Theta Inhibitors for Treating Autoimmune or Inflammatory Diseases

R. W. Sabnis
article en

Abstract

Provided herein are novel compounds as PKC-theta inhibitors, pharmaceutical compositions, use of such compounds in treating autoimmune or inflammatory diseases, and processes for preparing such compounds.

ACS Medicinal Chemistry LettersVol. 17(2)
Zero hunger
Openalex Percentile: Top 95%
Protein Kinase Regulation and GTPase Signaling
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Novel Compounds as PKC-Theta Inhibitors for Treating Autoimmune or Inflammatory Diseases — R. W. Sabnis · ACS Medicinal Chemistry Letters (2026) | TGRS Research Map | TGRS